Value in Myeloma Care: Myth or Reality

Area of Science:

• Oncology
• Health Economics
• Patient-Centered Care

Background:

• Multiple myeloma (MM) care has advanced significantly, yet it still causes substantial morbidity.
• Long-term MM treatment leads to considerable financial toxicity for patients and high societal costs.

Purpose of the Study:

• To critically examine why value in MM treatment is currently perceived as a myth.
• To propose actionable strategies for enhancing the value of MM care.

Main Methods:

• Review of current MM treatment paradigms and their associated costs.
• Analysis of patient-centered outcomes, including financial toxicity and quality of life.
• Exploration of potential solutions for cost reduction and value augmentation.

Main Results:

• Current MM treatment value is undermined by high drug costs and indefinite therapy duration.
• Patient-centered outcomes like financial toxicity and quality of life are significantly impacted.
• Several pathways exist to improve MM care value, though challenges remain.

Conclusions:

• Achieving value-based care in MM requires addressing drug costs and treatment duration.
• Strategies include promoting generic drugs, increasing clinical trial funding, and patient-centric trial design.
• Minimal residual disease (MRD)-guided de-escalation offers a potential avenue for optimizing treatment value.